JSPR logo

JSPR Jasper Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$10.75
-0.77 (-6.68%)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercializa…

Market Cap: $11.92Mjaspertx.com

Price

No data yet.

Social Signal Score

34
5d
—
30d
30
3 mentions
—
60d
34
5 mentions
—
90d
37
6 mentions
—
news: 6

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 8Hold 5Sell 0Strong Sell 0
Avg price target$2-81.4%
Low $2Median $2High $2
Current Consensus

Revenue

$8.00M
$0.00$2.67M$5.33M$8.00M
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-131.41
$-139.12–$-122.90
4 analysts
FY2026
$-20.66
$-20.66–$-20.66
2 analysts
FY2027
$-15.51
$-18.10–$-12.93
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jeetinder Singh Mahal
Sector
Healthcare
Industry
Biotechnology
Employees
22
Beta
3.31
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
-6.44
jaspertx.com